Automated GMP-compliant PSC banking in a closed system

Tuesday 09:00 PDT / 12:00 EDT / 16:00 GMT / 17:00 CET

Sponsor

Automated GMP-compliant PSC banking in a closed system

Human pluripotent stem cells (PSCs) hold great potentials in regenerative therapies. In this webinar, Chao will first present the closed and automated CliniMACS Prodigy® Adherent Cell Culture process and the established PSC expansion and differentiation workflows. Afterwards, Rafal will shortly introduce the CiRA Foundation, an offshoot of the Center for iPS Cell Research and Application (CiRA), Kyoto University that assumed control of CiRA's management of induced pluripotent stem cells (iPS cells) and acts as a bridge for the transfer of iPS cell technology to the industry. Then, he will discuss the progress of protocol optimization for large-scale expansion of clinical grade iPS cells with the CliniMACS Prodigy Adherent Cell Culture process.

How to build customized PSC expansion and differentiation processes in an automated, scalable, and closed manufacturing system.
How to effectively transition from manual iPS cell expansion protocols to automated and functionally closed cell manufacturing.
What modifications of the manual iPS cell expansion protocol are required for the CliniMACS Prodigy Adherent Cell Culture process.

Chao Sheng PhD

Global Product Manager - Regenerative Medicine at Miltenyi Biotec

Chao performed his Ph.D. projects at the Chinese Academy of Sciences in Beijing, China, and then continued his Postdoc studies at the University of Bonn and the German Center for Neurodegenerative Diseases in Bonn, Germany, focusing on cell fate (re)programming. Chao joined Miltenyi Biotec as a Product Manager for the Regenerative Medicine portfolio in 2018. He and his colleagues are developing automated, closed, and scalable adherent stem cell cultivation technologies based on the widely used CliniMACS Prodigy® Cell Manufacturing Platform.

Rafal Krol PhD

Principal Investigator at CiRA Foundation

Rafal has obtained a M.D. degree in 1996 and worked as a pediatric surgeon at the Medical University of Lódz, Poland.In 2005, he received a Japanese MEXT scholarship and started a doctoral course at Kobe University, where he became first interested in induced pluripotent stem cells (iPS cells).After obtaining the Ph.D. degree in 2010, he held several postdoctoral positions in Japan and received an iPS cell generation and maintenance training at Kumamoto University.In January 2019, he joined the Research and Development Section in Facility for iPS Cell Therapy, Center for iPS Cell Research and Application, Kyoto University, headed by Prof. Shinya Yamanaka, where he is working on the manufacturing of iPS cells for clinical applications.In 2020, the facility became a core of newly established CiRA Foundation (https://www.cira-foundation.or.jp/e/), which is a public interest incorporated foundation intended to serve as a bridge between academia and industry.